



Pledging my time: In utero exposure to acetaminophen and childhood neurodevelopment

Dear editor,

In the recent issue of PPE, Ricci et al.¹ present a systematic review and meta-analysis on in utero exposure to acetaminophen and childhood ADHD and ASD. It is a technically well designed and meticulous meta-analysis. It is well written with many appropriate considerations on limitations and cautiousness with respect to interpretation. Despite many similar papers in recent years, it is also a justifiable updated analysis given some new datasets. Unfortunately, I also believe that the authors do not address several major principal and paper-specific issues to a necessary extent.^{2,3}

1. Heritability of ADHD/ASD and the lack of or poor confounder control for almost all the papers included in the meta-analysis. The authors quote 'maternal migraine and fewer' as important confounders from the excellent bias analysis paper by Marsawa et al.⁴ Upon adjustment for parental ADHD and ASD, these apparent associations were substantially attenuated.
2. This meta-analysis only in passing mentions heritability and confounding by parental ADHD/ASD.
3. Major methodological issues with, especially, Ji 2000,^{3,5} but also some of the other papers included.
4. A major point of the very good paper by Ystrom⁶ paper is not discussed. Preconceptional paternal exposure yielded similar associations as did maternal exposure during pregnancy. This is important as it substantiates the existence of a common denominator in the form of environmental and/or heritable factors.

The evolution and use of systematic tools and guidelines to assess the quality and bias in observational research are an important progress. But sometimes, these tools do not suffice to evaluate the inherent quality of a study, i.e. according to the authors, the quality and risk of bias assessment of the Li 2000 paper qualify this for the meta-analysis. I flag this paper for severe selection bias to an extent that it does not hold any external validity and forcing these data through the meta-analysis funnel will not advance science, help our understanding of the issue or provide a fair or meaningful presentation. Other methodological issues reveal themselves below the surface of the GRADE, STROBE, PRISMA, SWiM and SAQOR tools. I encourage the authors to revisit the paper by Ji et al in detail and address these questions:

- a. Why did every (996 of 996) single umbilical sample contain acetaminophen?
- b. What comprises the control group in this study?
- c. How is the author construct 'acetaminophen burden', essential to exposure stratification, validated?
- d. To what extent is parental ADHD or ASD controlled for?
- e. What are the consequences to the external validity of the study when the incidence of ADHD/ASD and combinations thereof is about 37% among all follow-ups, and only 33% were not assigned a 'developmental disability' diagnosis?
- f. How many women received acetaminophen as an analgetic during birth?
- g. In these cases, are umbilical cord acetaminophen concentrations meaningful or plausible in the context of childhood neurodevelopment?

I have no issues with different positions on the evaluation and synthesis of scientific papers. But it is important to address pivotal studies beyond the screening tools, especially on controversial issues.

CONFLICT OF INTEREST STATEMENT

The author declares no conflicts of interest.

Per Damkier

Department of Clinical Pharmacology, Odense University
Hospital, Odense, Denmark

Correspondence

Per Damkier, Department of Clinical Pharmacology, Odense
University Hospital, Odense, Denmark.
Email: pdamkier@health.sdu.dk

ORCID

Per Damkier <https://orcid.org/0000-0003-0591-7187>

REFERENCES

1. Ricci C, Albanese CM, Pablo LA, et al. In utero acetaminophen exposure and child neurodevelopmental outcomes: systematic review and meta-analysis. *Paediatr Perinat Epidemiol.* 2023;1-12. doi:10.1111/ppe.12963 Online ahead of print.
2. Damkier P. Simple twist of fate: In utero exposure to acetaminophen and risk of childhood attention deficit hyperactivity disorder. *Paediatr Perinat Epidemiol.* 2020;34(3):230-232. doi:10.1111/ppe.12654



3. Damkier P, Cleary B, Weber-Schoendorfer C, et al. Handle with care – interpretation, synthesis and dissemination of data on paracetamol in pregnancy. *Nat Rev Endocrinol.* 2022;18(3):191. doi:10.1038/s41574-021-00605-y
4. Masarwa R, Platt RW, Filion KB. Acetaminophen use during pregnancy and the risk of attention deficit hyperactivity disorder: a causal association or bias? *Paediatr Perinat Epidemiol.* 2020;34(3):309-317. doi:10.1111/ppe.12615
5. Ji Y, Azuine RE, Zhang Y, et al. Association of Cord Plasma Biomarkers of In utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism Spectrum disorder in childhood. *JAMA Psychiat.* 2020;77(2):180-189. doi:10.1001/jamapsychiatry.2019.3259
6. Ystrom E, Gustavson K, Brandlistuen RE, et al. Prenatal exposure to acetaminophen and risk of ADHD. *Pediatrics.* 2017;140(5):e20163840. doi:10.1542/peds.2016-3840